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Abstract
Introduction:  Minimal residual disease (MRD), detected based on immunoglobulin and T-cell receptor (Ig/TCR) gene
rearrangements as markers of residual leukemic cells, is currently the most reliable prognostic factor in acute lymphoblastic
leukemia (ALL). A feasibility study is presented of the standard strategy for the identification of Ig/TCR targets for MRD
diagnostics in Polish ALL patients by identifying Ig/TCR gene rearrangement pattern using standard primer sets and proto-
cols.
Materials and Methods: The PCR-heteroduplex approach based on BIOMED-1 and BIOMED-2 protocols (recommended
as the European standard) was used to detect IGH, IGK-Kde, TCRD, TCRG, and TCRB rearrangements in 58 Polish B-cell
precursor ALL patients. Sequencing and homology analysis between the obtained and germline Ig/TCR sequences enabled
identification of the rearrangements. The U-Gauss test was used for statistical analysis of the Ig/TCR rearrangement pattern
in Polish patients compared with relevant data on other nationalities.
Results: The following pattern was identified: IGH: 83% (VH-JH: 74%, DH-JH: 9%), IGK-Kde: 41%, TCRD: 78% (incom-
plete TCRD: 55%, Vδ2-Dδ3: 45%, Dδ2-Dδ3: 21%, Vδ2-Jα: 35%), TCRG: 50%, and TCRB: 13%. Considerable convergence
of the Ig/TCR pattern in Polish patients and those of other nationalities (mainly West Europeans) was demonstrated.
Statistically relevant differences were only found between the incidence of DH-JH in Polish (9%) and Dutch patients (24%;
p<0.05) and Polish and Italian patients (19%; p<0.05), VH-JH in Polish (74%) and Chilean patients (100%; p<0.05), and
TCRG in Polish (50%) and Brazilian patients (69%; p<0.05). 
Conclusions: The convergence of Ig/TCR patterns in Polish and European patients indicates that the strategy for Ig/TCR tar-
get identification based on standard primers and protocols might be directly used for the construction of Polish standards
and recommendations for MRD diagnostics.
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INTRODUCTION
The level of residual leukemic cells (minimal resid-
ual disease, MRD) is currently the most reliable prog-
nostic factor in acute lymphoblastic leukemia (ALL).
Detection and quantitative assessment of MRD per-
formed at fixed time-points during ALL treatment
enables precise stratification of patients into risk groups
and appropriate adjustment of treatment intensity. The
clinical significance of MRD assessment in risk-adaptedmanagement of ALL is already well documented [7, 26,
31].
Molecular diagnostics of MRD is currently most
widely performed with the use of the real-time quantita-
tive polymerase chain reaction approach (RQ-PCR) and
rearranged immunoglobulin (Ig) and T-cell receptor
(TCR) genes as patient-specific “fingerprint-like” mark-
ers of residual leukemic cells [25]. Protocols for MRD
diagnostics (including the identification of Ig/TCR
rearrangements and RQ-PCR MRD assessment) as well
as guidelines for interpreting the quantitative data have
been highly standardized through international collabo-
ration, mainly within the confines of the BIOMED-1
Concerted Action, the BIOMED-2 Concerted Action,
and the European Study Group on MRD Detection in
ALL [14, 24, 30]. These standards are routinely applied,
particularly in Western Europe, for the MRD-based
stratification of ALL treatment. However, in some coun-
tries ALL therapeutic protocols are still being applied in
which MRD diagnostics is not obligatory for risk-group
assessment, such as the ALL-IC-BFM 2002 protocol. In
these countries, like in Poland, an urgent need for the
development of routine MRD diagnostics is indicated.
The introduction of MRD assessment into clinical prac-
tice might be performed in a reasonably cost- and labor-
effective manner through direct implementation of the
existing European standards.
European collaboration implies that these standards
were based on the rearrangements most commonly
identified in patients from West European countries.
However, according to some authors, the frequencies of
Ig/TCR gene rearrangements might differ significantly
in various populations [16–18]. Scrideli et al. [17] posed
an hypothesis concerning socio-economic-based diversi-
ty of Ig and TCR gene rearrangement patterns (the fre-
quency of rearrangements in individual loci and the uti-
lization of Ig/TCR genes in the rearrangements), which
might have implications for the choice of primers for
MRD diagnostics. Therefore, for those aiming to imple-
ment MRD assessment in routine molecular diagnos-
tics, it appears justified to assess the applicability of the
chosen protocols and primer sets for efficient detection
of MRD markers. Characterization of the rearrange-
ment pattern, particularly the identification of distinc-
tive features of the pattern in the target population,
enables modification of the protocols to ensure success-
ful selection of MRD markers. Since MRD diagnostics
is currently being developed in Poland, we performed
a feasibility study of the standard strategy for the identi-
fication of Ig/TCR MRD targets in Polish patients. We
also evaluated the need for modifying European stan-
dards due to the specificity of the Polish pattern. To
address these goals we performed an identification of
the Ig/TCR gene rearrangement pattern using standard
primer sets and protocols and compared the identified
pattern with those reported for patients of other, main-
ly European, nationalities. 
We previously reported our preliminary results on
the identification of the antigen receptor gene
rearrangement pattern in a group of 23 Polish pediatric
B-cell precursor ALL patients (BCP-ALL) [9]. In the
present study we identified the rearrangement pattern in
a larger cohort of 58 BCP-ALL children (including the
23 patients from our previous study), which enabled ver-
ification of our preliminary observations using statistical
methods. We demonstrated convergence of the Ig/TCR
rearrangement pattern identified in Polish patients with
the results published for other European cohorts. This
finding supports the idea of direct implementation of the
standard strategy into MRD diagnostics in our country.
Moreover, in the present study we assessed the efficacy
of detecting Ig and TCR gene rearrangements using
exclusively the singleplex PCR approach vs. a combined
singleplex-multiplex approach, which might be applied
for the design of a cost- and labor-effective MRD diag-
nostic approach. Our results might be useful for other
countries undertaking the development of MRD diag-
nostics based on available European standards. 
MATERIALS AND METHODS
Patients
We studied 58 consecutive patients with newly diag-
nosed BCP-ALL being treated according to the ALL IC
BFM 2002 protocol, recruited (based on written
informed consent and the availability of biological mate-
rial of suitable amount and quality) between 2003–2006
in two hematological centers, Poznañ and Bydgoszcz.
The group was representative of the country in view of
the considerable homogeneity of the Polish population.
The cohort of patients consisted of 27 females and 31
males aged 1.1–16.7 years at the time of diagnosis (mean
age: 6.9 years). Diagnosis of BCP-ALL was based on the
French-American-British classification and flow cyto-
metric immunophenotyping with the use of a standard
set of monoclonal antibodies [15].
Material
Bone marrow samples obtained before the commen-
cement of treatment were subjected to Ficoll-Paque
(Pharmacia Biotech, Sweden) or Gradisol L (Aqua-Me-
dica, Poland) density gradient centrifugation for mono-
nuclear cell (MNC) separation. Three methods were
used for DNA extraction; the majority of DNA extrac-
tions were performed using QIAamp DNA Blood Mini
Kit (Qiagen, Germany), some using the NaCl precipita-
tion-based protocol (salting-out method), and a few
MNC samples were processed by boiling in Qiagen PCR
buffer (1 × containing 1.5 mM MgCl2, 95°C, 10 min).
Detection of Ig/TCR gene rearrangements
by PCR amplification
Detection of Ig/TCR rearrangements was performed
with the use of the BIOMED-1 and BIOMED-2 proto-
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BIOMED-2 primers. In all 58 patients a singleplex PCR
approach using the BIOMED-1 primers was applied for
amplification of the rearrangements IGK-Kde, incom-
plete  TCRD  (Vδ2-Dδ3, Dδ2-Dδ3), and TCRG  [14].
Complete IGH rearrangements [33] and TCRD/A (Vδ2-
-Jα29) rearrangements were also detected with the sin-
gleplex approach using standard “non-BIOMED”
primers [20]. Moreover, in 23 of these patients a multi-
plex approach was applied for detection of rearranged
TCRB genes using BIOMED-2 primers [30].
Incomplete IGH [22] and Vδ2-Jα [20] rearrangements
were also detected in these 23 patients with the multi-
plex approach using standard “non-BIOMED” primers.
Amplification was performed in a 50-µl volume contain-
ing 50 ng of genomic DNA, 200 µM of each dNTP, 7 and
14 pmol of the 5’ and 3’ oligonucleotide primers
(Sigma/Oligo, Poland) in singleplex reactions or 10
pmol of the 5’ and 3’ primers (Sigma-Aldrich, USA) in
the multiplex approach, 1.5 and 1.5–3 mM MgCl2 (in the
singleplex and multiplex approach, respectively), 0.5 U
of TaqGold (Applied Biosystems, USA) or 0.65 U of
HotStar-Taq (Qiagen, Germany) polymerase in single-
plex reactions, and 1–2 U TaqGold (Applied Bio-
systems, USA) polymerase in the multiplex approach. In
each PCR, negative and relevant positive controls were
amplified. The cycling conditions were 95°C for 7 min,
35 × (94°C for 45 s, 60°C for 90 s, and 72°C for 2 min),
and 72°C for 10 min. Standard agarose gel elec-
trophoresis was used to select the PCR products con-
taining the specific amplicons for further analysis.
Heteroduplex analysis
Heteroduplex analysis for discriminating between
monoclonal and polyclonal PCR products derived from
clonal leukemic cells and polyclonal reactive lympho-
cytes, respectively, was performed according to a stan-
dard protocol [11]. Briefly, the PCR products were
denaturated (94°C, 5 min) and subsequently renaturat-
ed (4°C, 1 h) to allow duplex formation. The samples
were immediately loaded onto 6% non-denaturating
polyacrylamide gel, run in 0.5×TBE buffer, and stained
with ethidium bromide. Detection of homoduplexes
(renaturation of identical DNA single strands) indicated
monoclonality. Detection of heteroduplexes (renatura-
tion of DNA strands of partially different sequence cor-
responding to the junction between the rearranged
genes) was interpreted according to the migration pat-
tern as a biclonal/biallelic rearrangement (mostly two
homoduplex and two heteroduplex bands, alternatively
co-migrating) or oligoclonality (more than two homod-
uplex and heteroduplex bands, a “PCR product lad-
der”). A smear of PCR products indicated polyclonality.
Identification of rearrangements via sequence analysis
Monoclonal PCR products were processed with the
QIAquick PCR Purification Kit (Qiagen, Germany) or
were sequenced directly. Excision of the appropriate
homoduplex or heteroduplex bands followed by DNA
elution and precipitation was performed if more than
one amplicon was detected in a single PCR
(biclonal/biallelic rearrangement or multiplex PCR).
Sequencing with the use of amplification primers [14,
20, 22, 30, 33] was carried out in both directions. The
identification of rearranged genes was performed by
comparison of the obtained sequences with germline
sequences available in the databases IMGT®
(http://imgt.cines.fr; European Bioinformatics Institute,
Montpellier, France) and VBASE (http://www.mrc-
cpe.cam.ac.uk; Center for Protein Engineering,
Cambridge, UK). Homology between the sequences was
analyzed with the use of DNAPLOT (W. Müller, H-
H.Althaus, University of Cologne, Germany) and
SeqMan II Lasergene v. 6 software (DNASTAR Inc.,
Madison, WI, USA).
RESULTS
To determine the pattern of the rearrangements, i.e.
the frequency of the rearrangements in individual
Ig/TCR loci and the utilization of V (variable), D (diver-
sity), and J (joining) genes, the rearrangements detect-
ed in the group studied were identified and character-
ized. Moreover, to address the efficacy of detection of
Ig/TCR gene rearrangements with the use of the single-
plex PCR vs. the combined singleplex and multiplex
approach, relevant results obtained in the group of 58
patients were compared with those obtained for the sub-
group of 23 patients, respectively.
Detection and identification 
of Ig/TCR gene rearrangements
In total, 211 clonal Ig/TCR gene rearrangements
were detected (see Table 1 for a summary) comprising
60 IGH rearrangements (58 complete VH-(DH)-JH and
2 incomplete DH-JH), 33 IGK rearrangements (24
Vκ-Kde and 9 Intron-Kde), 48 incomplete TCRD
rearrangements (34 Vδ2-Dδ3 and 14 Dδ2-Dδ3), 15
TCRD/A rearrangements (Vδ2-(Dδ3)-Jα), 51 TCRG
rearrangements, and 4 TCRB rearrangements (3 com-
plete Vβ-(Dβ)-Jβ and 1 incomplete Dβ-Jβ). 
In the singleplex PCR approach, at least one clonal
rearrangement was detected in 97% (56/58) of the BCP-
-ALL patients and at least two in 86% (50/58) of the
patients. Insufficient quality of the DNA samples was
excluded by amplification of the 100-, 200-, 400-, and
600-bp DNA fragments in multiplex PCR (BIOMED-2
Control Gene tube) in the case of the two patients in
whom no PCR products were detected [30]. The num-
ber of rearrangements detected per patient ranged from
0 to 8, both cases occurring with a frequency of 3%
(2/58), with 2 rearrangements as the most frequent
number of rearrangements/patient (mode) occurring
with a frequency of 24% (14/58). The mean number of
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Table 1. Ig/TCR gene rearrangements found in the group of Polish B-cell precursor ALL patients
Patient IGH IGK-Kde Incomplete TCRD Vδ2-Jα TCRG TCRB Total
1.1 VH3.66-DH1.26-JH3 Vδ2-Dδ33
Vδ2-Dδ3
3.1 VH4.39-JH6 Vκ3d20-Kde Vδ2-Dδ3-Jα29 Vγ9-Jγ1.3 6
Vγ4-Jγ1.3
VγI-Jγ1.3/2.3a
5.1 VH3.21-DH2.8-JH6 Dδ2-Dδ32
7.1 VH3.9-DH5.5-JH4 2
DH-JHa
10.1 VH1.17-DH2.2-JH5 Vδ2-Dδ3V γ4-Jγ2.1 6
Vδ2-Dδ3 ψVγ11-Jγ2.1
Dδ2-Dδ3
15.1 Vκ1.16-Kde Vγ4-Jγ2.3 3
Vκ2.30-Kde 
18.1 Vδ2-Dδ32
Dδ2-Dδ3
19.1 Vγ5-Jγ2.3 1
20.1 VH2.26-JH6 Vκ1.37-Kde Vδ2-Jαa Vγ8-Jγ2.1 5
Vγ9-Jγ2.3
22.1 VH2.5-DH2.8-JH6 Vδ2-Dδ3V γ3-Jγ1.1 4
VγI-Jγ1.3/2.3b
23.1 VH1.3-JH6 1
34.1 VH1.3-DH6.13-JH3 Vκ2.24-Kde Vδ2-Dδ3V δ2-Jα48 Vγ3-Jγ1.1 8
VH2.5-DH2.15-JH4 Vκ2.30-Kde Vγ4-Jγ1.1
37.1 VH2.26-DH3.9-JH4 Vκ2.30-Kde Dδ2-Dδ3V γ2-Jγ2.3 6
VH4.30-JH2 Vγ9-Jγ2.3
40.1 VH3.13-DH2.2-JH3 Vδ2-Dδ3-Jα48 2
42.1 VH1.8-DH4.4-JH4 Vδ2-Jαa ψVγ11-Jγ2.3 5
VH6.1-JH5 Vδ2-Jαa
43.1 VH3.13-DH3.3-JH4 Vδ2-Dδ32
44.1 VH2.5-DH2.8-JH6 Dδ2-Dδ3V γ3-Jγ2.1 7
VH4/6-JHa Vγ5-Jγ2.3
VH4/6-JHa VγI-Jγ1.3/2.3a
45.1 Vκ2.30-Kde Vδ2-Dδ3V δ2-Dδ3-Jα29 Vγ3-Jγ2.3 Dβ2-Jβ2.7 6
Vγ9-Jγ1.3
46.1 VH1.3-DH6.6-JH2 Vδ2-Dδ3V γ5-Jγ2.3 5
Vδ2-Dδ3
Dδ2-Dδ3
47.1 VH3.21-DH3.9-JH4 Vκ1.33-Kde Dδ2-Dδ3V δ2-Jαa Vγ2-Jγ2.3 7
Intron-Kde Dδ2-Dδ3
48.1 VH3.7-DH6.13-JH6 2
DH-JHa
49.1 VH3.49-DH3.22-JH4 Vκ1.16-Kde Dδ2-Dδ3V δ2-Jα29 Vβ-(Dβ)-Jβa 6
Vβ-(Dβ)-Jβa
50.1 VH1.2-DH6.6-JH4 Vδ2-Dδ3V γ9-Jγ2.3 Vβ-(Dβ)-Jβa 5
VH4.31-DH2.2-JH4
51.1 VH1.69-DH1.14-JH4 Vκ1.8-Kde Vδ2-Dδ3-Jα29 8
VH4.59-DH4.17-JH4 Vκ3.15-Kde Vδ2-Jα29
VH3-JHa
VH3-JHa
52.1 VH3.64-DH5.24-JH4 Intron-Kde Vδ2-Dδ3V γ2-Jγ1.1 6
VH6.1-DH6.19-JH4 Vγ9-Jγ2.3
54.1 VH4.61-JH6 Dδ2-Dδ32
57.1 VH3-JHa Vγ4-Jγ2.3 3
VH3-JHa
58.1 Intron-Kde Vδ2-Dδ32
60.1 VH4/6-JHb 1
61.1 VH4.39-DH3.22-JH4 Vδ2-Dδ32
64.1 VH3.7-JH4 Vδ2-Dδ32
68.1 Vκ2.30-Kde Vδ2-Dδ3V γ5-Jγ1.1 5
Intron-Kde Vδ2-Dδ3rearrangements/patient was 3.6. In the case of the 23
patients (singleplex-multiplex approach), at least one
clonal rearrangement was detected in 100% of the
patients and at least two in 91% (21/23) of the patients.
The number of rearrangements/patient ranged from 1
(2/23, 9%) to 8 (1/23, 4%), with a mode of rearrange-
ments of 2 (6/23, 26%) and a mean of 4.2. The distribu-
tions of the number of rearrangements/patient detected
in the groups of 58 and 23 patients are presented in
Fig. 1.
In total, 179 rearrangements were identified, com-
prising 48 IGH rearrangements (37 VH-DH-JH and 11
VH-JH), 32 IGK rearrangements (23 Vκ-Kde and 9
Intron-Kde), 48 incomplete TCRD rearrangements (34
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Table 1. Continued
Patient IGH IGK-Kde Incomplete TCRD Vδ2-Jα TCRG TCRB Total
69.1 VH3.53-DH3.3-JH6 Vδ2-Dδ3V δ2-Jα29 Vγ2-Jγ1.1 5
Vγ3-Jγ1.3
70.1 VH3.21-JH4 Vκ1.33-Kde Vδ2-Dδ35
Intron-Kde Vδ2-Dδ3
72.1 VH3.23-JH4 Vκ1.17-Kde Vδ2-Jα29 4
Vκ3.20-Kde 
73.1 VH4.61-DH2.2-JH6 Intron-Kde  ψVγ11-Jγ2.3 3
74.1 VH3-JHb Intron-Kde Dδ2-Dδ3V δ2-Jα29 Vγ9-Jγ2.3 6
Vδ2-Dδ3
75.1 0
77.1 VH3.23-DH2.8-JH5 Vκ1.27-Kde Vγ9-Jγ1.3 4
VH6.1-DH3.3-JH5
78.1 Vγ9-Jγ1.1 2
ψVγ11-Jγ2.3
79.1 VH3.30-DH4.4-JH4 Vκ1.9-Kde Vδ2-Dδ3V γ9-Jγ2.3 6
VκI-Kdea Vγ2-Jγ2.3
80.1 VH1.8-DH2.8-JH4 Vκ1.33-Kde 3
Vκ2.24-Kde 
84.1 VγIV-Jγ1.1/2.1a 4
VγIV-Jγ1.1/2.1a
VγI-Jγ1.3/2.3a
VγI-Jγ1.3/2.3a
85.1 Vδ2-Dδ3V γ2-Jγ2.3 5
Dδ2-Dδ3V γI-Jγ1.1/2.1a
VγI-Jγ1.1/2.1a
86.1 VH1.3-DH2.2-JH2 1
91.1 Vδ2-Dδ31
94.1 Vκ4.1-Kde Vδ2-Dδ3V δ2-Jα29 3
95.1 VH3.23-DH1.7-JH4 1
96.1 Vκ2.30-Kde Vγ2-Jγ2.3 3
Vγ9-Jγ2.3
97.1 VγI-Jγ1.1/2.1a 2
VγI-Jγ1.1/2.1a
100.1 VH5.51-DH1.26-JH4 Vκ2.30-Kde Vδ2-Dδ3V γ5-Jγ2.3 7
VH1.46-DH1.26-JH4 Vδ2-Dδ3V γI-Jγ1.3/2.3a
102.1 VH3-JHa Vδ2-Dδ34
VH3-JHa Vδ2-Dδ3
103.1 VH2.26-DH6.13-JH6 Dδ2-Dδ34
Dδ2-Dδ3
Vδ2-Dδ3
104.1 VH6.1-JH4 Vδ2-Dδ3V γ9-Jγ2.3 3
106.1 0
108.1 VH2.26-DH6.13-JH4 2
VH3.13-DH3.10-JH4
110.1 VH3.23-JH6 Intron-Kde Vδ2-Dδ34
Vδ2-Dδ3
113.1 VH3.43-DH3.3-JH4 Intron-Kde  2
aClonal rearrangements (based on heteroduplex analysis) not identified due to substantial proximity of migrating duplexes; it was
impossible to cut the separate bands from the gel for further sequencing.
bMonoclonal rearrangements (based on heteroduplex analysis); V(D)J genes not unequivocally identified despite repeated
sequencing.Vδ2-Dδ3 and 14 Dδ2-Dδ3), 11 TCRD/A rearrangements
(6 Vδ2-Jα29, 3 Vδ2-Dδ3-Jα29, 1 Vδ2-Jα48, and 1 Vδ2-
-Dδ3-Jα48), 39 TCRG rearrangements, and 1 TCRB
(Dβ-Jβ) rearrangement. In Table 1 are listed the
Ig/TCR gene rearrangements found in the total group
of patients.
Pattern of Ig/TCR gene rearrangements
The pattern of the frequencies of rearrangements
detected in the individual Ig/TCR loci is presented in
Table 2. The frequencies are depicted either for the
total group of 58 patients (Ig/TCR loci screened in the
singleplex approach) or for the subgroup of 23 patients
(rearrangements detected in the multiplex approach,
e.g. DH-JH, or in the combined singleplex-multiplex
approach, e.g. total frequency for the IGH locus). 
Moreover, the frequencies of variable, diversity, and
joining genes in the rearrangements identified in the
individual Ig/TCR loci were studied to determine the
pattern of V(D)J utilization. The most relevant results
follow. Rearrangements in the IGH locus most frequent-
ly involved the VH3, VH1, VH2, and VH4 family mem-
bers in 40% (19/48), 21% (10/48), 15% (7/48), and 15%
of the IGH rearrangements, respectively, DH2 (30%,
11/37), DH3 (24%, 9/37), and DH6 (19%, 7/37) family
members, and JH4 (54%, 26/48), and JH6 (25%, 12/48)
genes. Of the rearrangements in IGK locus, Vκ1 (43%,
10/23) and Vκ2 (39%, 9/23) family members were most
frequently identified. In the TCRD  locus, Vδ2-Dδ3
(71%, 34/48) rearrangements were predominantly iden-
tified over Dδ2-Dδ3 (29%, 14/48). In TCRD/A
rearrangements, Vδ2 or Vδ2-Dδ3 genes were found to
be rearranged with only two of the Jα genes, Jα29 in
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Fig. 1. Distribution of the number of rearrangements per patient
detected in a total group of 58 patients (in a singleplex PCR
approach) and in a subgroup of 23 patients (in a combined single-
plex and multiplex PCR approach).
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Table 2. The pattern of the frequency of the rearrangements detected in Ig/TCR loci in Polish B-cell precursor ALL patients
Number of patients Frequency
subjected to  with at least one  of rearrangements
PCR screening rearrangement detected
Ig IGH VH-(DH)-JH 58 43 74%
DH-JH 23 2 9%
total IGH 58a, 23b 43a, 19b 74%a, 83%b
IGK-Kde Vκ-Kde 58 18 31%
Intron-Kde 58 9 16%
total IGK-Kde 58 24 41%
Total Ig 58a, 23b 49a, 21b 84%a, 91%b
TCR TCRD incomplete Vδ2-Dδ3 58 26 45%
Dδ2-Dδ3 58 12 21%
total inc. TCRD 58 32 55%
Vδ2-Jα Vδ2-(Dδ3)-Jα29 58 8 14%
Vδ2-(Dδ3)-Jα 23 5 22%
total Vδ2-Jα 58a, 23b 13a, 8b 22%a, 35%b
Total TCRD 58a, 23b 38a, 18b 66%a, 78%b
TCRG Vγ-Jγ 58 29 50%
TCRB Vβ-(Dβ)-Jβ 23 2 9%
Dβ-Jβ 23 1 4%
total TCRB 23 3 13%
Total TCR 58a, 23b 47a, 20b 81%a, 87%b
Total Ig/TCR   58a, 23b 56a, 23b 97%a, 100%b
a, bRefer to groups of patients in whom particular rearrangements were screened for in either the singleplex or the combined sin-
gleplex-multiplex PCR approach.82% (9/11) and Jα48 in 18% (2/11), of the rearrange-
ments. In the TCRG locus the rearrangements most fre-
quently involved VγI (59%, 23/39) and VγII (31%, 12/39)
family member genes and Jγ2.3 (59%, 23/39) gene. 
Comparison of Ig/TCR rearrangement pattern 
in Polish patients and other nationalities
The frequencies of the rearrangements detected in
individual Ig/TCR loci in the group of Polish patients
were compared with the data obtained (using the PCR
approach) in patients of other, mainly European,
nationalities. The results of the analysis are presented in
Table 3. The U-Gauss test was used to verify the statis-
tical significance of the differences observed between
the frequencies of the rearrangements in the studied
group and those of other nationalities. The only statisti-
cally relevant differences (p values <0.05) were found
between the incidence of DH-JH rearrangements in
Polish (9%), Dutch (24%), and Italian patients (19%;
p<0.05 in both tests), the frequency of VH-JH
rearrangements in Polish (74%) and Chilean patients
(100%; p<0.05), and the frequency of rearrangements
in the TCRG locus in Polish (50%) and Brazilian
patients (69%; p<0.05). In the remaining tests the p val-
ues were greater than 0.05.
DISCUSSION
The current standards for MRD diagnostics in lym-
phoproliferative disorders are based on analyses per-
formed in patients from Western European countries.
Thus the standard primers are aimed at the detection of
the Ig and TCR gene rearrangements most frequently
identified in these patients. However, there are data on
inter-population diversity in the pattern of rearrange-
ments and the existence of “population-specific” char-
acteristics of the pattern [16, 17]. The impact of ethnic
or socio-economic factors (e.g. earlier or greater expo-
sure to bacterial and viral antigens) on the frequency of
the rearrangements has been suggested [17]. Although
this hypothesis still needs verification, it is beyond doubt
that the determination of a specific Ig/TCR gene
rearrangement pattern in a given population might have
implications for the choice of primers for detecting the
rearrangements. Therefore, this paper might be of par-
ticular interest for those aiming at introducing the
European standards into molecular diagnostics of
MRD.
Considerable convergence of the rearrangement
pattern in Polish patients and those identified in
European nationalities (mainly West Europeans) is
demonstrated by comparison of the frequencies of the
rearrangements in the Ig/TCR loci (Table 3). Except for
the lower incidence of DH-JH rearrangements in the
present study compared with those in Dutch [27] and
Italian [10] patients (9% vs. 24% and 19%, respectively,
p<0.05 in both tests), no statistically significant differ-
ences are observed between the rearrangement patterns
in Polish and European patients. The lower frequency
of DH-JH rearrangements detected in the group stud-
ied is rather unlikely to be Polish specific. It is most
probably due to the fact that DH-JH rearrangements
M. Dawidowska et al.: Ig/TCR targets in ALL diagnostics 415
Table 3. Comparison of Ig/TCR gene rearrangement patterns in Polish patients and other nationalities identified by the PCR-het-
eroduplex approach
Study Country
Number Frequency of rearrangements in Ig/TCR loci [%]
of patients VH-JH DH-JH IGH IGK-Kde incomplete Vδ2-Jα TCRD TCRG TCRB
TCRD
Present study Poland 58a 74a 9b 83b 41a 55a 35b 78b 50a 13b
23b 45a(Vδ2-Dδ3)
21a(Dδ2-Dδ3)
van der Velden  The Nether- 271 82 24 88 43 40 (Vδ2-Dδ3) 46 72 58
et al. [27] lands 14 (Dδ2-Dδ3)
Germano et al. [10] Italy 53 77 19 83 42 62 62
Meleshko et al. [13] Belarus 67 78 63
51 (Vδ2-Dδ3) 45 
36 (Dδ2-Dδ3)
Barriga et al. [1] Chile 32 100
Scrideli et al. [17] Brazil 79 69
Szczepañski et al. [20] The Nether- 339 41
lands
Brumpt et al. [4] France 74c 92c 43d (Vδ2-Dδ3) 66c
23d
Cavé et al. [7] France  188 61 57
and Belgium
van der Velden  The Nether- 161 33
et al. [23] lands
a, b, c, dRefer to groups of patients in whom particular rearrangements were screened for; frequencies depicted in bold mean that
p<0.05 was obtained in the U-Gauss test. are detected in BCP-ALL patients at a relatively low
frequency combined with the small group of patients in
whom these rearrangements were studied (a subgroup
of 23 patients). We interpret the frequency of TCRB
rearrangements, in the present study lower (though not
significantly) than that reported for Dutch patients [23],
similarly. In contrast, the statistically significant differ-
ence found between the frequencies of rearrangements
in the TCRG locus in Polish and Brazilian patients
might support the hypothesis by Scrideli et al. [17] of the
socio-economic/ethnic-based diversity of rearrange-
ments patterns. However, more studies with patients of
different populations (from both “well-developed” and
“low-resources” countries) need to be conducted to
unequivocally determine the impact of these factors on
the rearrangement patterns.
To provide more detailed insight into the pattern of
Ig/TCR gene rearrangements in Polish patients, we also
analyzed utilization of the VH, DH, JH, Vκ, Jα, Vγ, Jγ
genes in the identified rearrangements and the profiles
of Vκ-Kde vs. intron-Kde and Vδ2-Dδ3 vs. Dδ2-Dδ3
rearrangements. Comparison of our results with pub-
lished data further confirms the convergence of the
rearrangement patterns of Polish patients and other
populations [2, 3, 5, 6, 8, 12, 13, 19, 20, 27–29, 32].
Moreover, to provide information potentially useful
for the design of a cost-effective MRD diagnostic
approach, we evaluated the efficiency of detecting
Ig/TCR gene rearrangements based on the singleplex
PCR approach and combined singleplex-multiplex
approach. Our data show that use of exclusively single-
plex PCRs (encompassing a broad gene rearrangement
panel: complete IGH,  IGK-Kde, Vδ2-Dδ3, Dδ2-Dδ3,
Vδ2-Jα29, and TCRG) enables detection of at least one
clonal rearrangement in 97% of BCP-ALL patients.
Application of additional multiplex reactions (for
incomplete IGH, Vδ2-Jα, and TCRB rearrangements)
results in the detection of at least one rearrangement in
100% of patients. The mean number of rearrangements
detected per patient reaches 3.6 in the singleplex
approach and 4.2 in the singleplex-multiplex approach.
Our results are in concordance with those reported by
other groups analyzing a comparably broad panel of
rearrangements (Table 4). 
However, it should be stressed that according to cur-
rent standards for MRD diagnostics [24, 25], the use of
at least two clonal rearrangements for detecting a malig-
nant clone is recommended to avoid false-negative
results as a consequence of the loss of an MRD marker
due to secondary and ongoing Ig/TCR rearrangements
and clonal evolution (described elsewhere) [21]. Our
data show that at least two clonal rearrangements are
detected in 86% of patients and in 91% of patients using
the singleplex and singleplex-multiplex approaches,
respectively. In a study by van der Velden et al. [27], at
least two MRD markers were detected in 95% of
patients in a combined singleplex-multiplex approach.
This is more than the frequency detected in the present
study, which might be because the cohort of Dutch
patients substantially outnumbered that of the Polish
patients (a subgroup of 23 patients for whom the com-
bined singleplex-multiplex approach was used).
Detection of at least one clonal rearrangement in
nearly 100% of patients and at least two rearrangements
in 86% of patients (with the singleplex approach) con-
trasted with the efficiency obtained in the singleplex-
multiplex approach (100 and 91%, respectively) indi-
cates the need for MRD diagnostics based on a broad
panel of rearrangements (detected preferably with both
the singleplex and multiplex approach). However, if cost
is a concern, it might be reasonable to perform single-
plex PCRs (encompassing a broad gene rearrangement
panel) as the basic PCR screening for all patients and, in
cases of unsatisfactory results of Ig/TCR-MRD marker
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Table 4. Frequency of detection of at least one and at least two clonal Ig/TCR gene rearrangements in Polish patients and in com-
parable studies of patients of other nationalities (based on the PCR-heteroduplex approach)
Study Country
Number
Rearrangements included in PCR screening Frequency of Mean
of pa- VH-JH DH-JH IGK-Kde
incom-
Vδ2-Jα
com- 
TCRG TCRB 
rearrange- number  of 
tients
plete plete ments  [%] rearrange-
TCRD TCRD min 1 min 2 ments
Present study Poland 58a +– + + + a – + – 97 86 3.6
23b –+ – – + b – – + 100 91 4.2
van der Velden The Nether- 271 + + + + + – + – >95 95 –
et al. [27] lands
Germano Italy 53 + + + + – + + – 100 – 4
et al. [10]
Szczepañski The  Nether-
et al. [21] lands 89 + + + + – – + – 98 – 4
– Relevant results were either not obtained or not reported in the cited papers.
aIn the total group of 58 patients, Vδ2-Jα29 was the only Vδ2-Jα rearrangement screened for in the singleplex PCR approach.
bIn the subgroup of 23 patients, Vδ2-Jα29 was screened for in the singleplex PCR approach; other Vδ2-Jα rearrangements were
screened for in the multiplex-PCR approach. 
Incomplete TCRD (Vδ2-Dδ3, Dδ2-Dδ3), complete TCRD (Vδ1-Jδ1, Vδ2-Jδ1, Dδ2-Jδ1).selection, to broaden the PCR screening with multiplex
PCRs. 
In conclusion, the considerable convergence in the
rearrangements patterns (frequencies of rearrangements
and profiles of V(D)J gene utilization) demonstrated in
Polish and European patients, including West European
nationalities, indicates no Polish-specific characteristics
of the rearrangement pattern. This enables us to con-
clude that in the case of Polish BCP-ALL patients, the
strategy for detecting Ig/TCR gene rearrangements
based on standard primers and protocols might be
directly applied in the molecular diagnostics of MRD.
Comparison of the efficiencies of detecting Ig/TCR
rearrangements in a given population with singleplex
and singleplex-multiplex PCR might be helpful in choos-
ing a cost- and labor-effective Ig/TCR-PCR screening
approach. It might be reasonable for other countries
aiming to introduce European MRD-standards to per-
form similar feasibility studies of the standard primers
and protocols in their particular populations of patients
to identify or exclude population-specific characteristics
of Ig/TCR rearrangement patterns and design an opti-
mal diagnostic setting for MRD analysis.
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